Sustained Release Implant

Between poor patient adherence and the inherent IOP peaks and troughs associated with eye drop-managed glaucoma, sustained-release medications are greatly needed, a presenter at the virtual OSN New York meeting said.

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.